[go: up one dir, main page]

WO2016112374A3 - Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) - Google Patents

Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) Download PDF

Info

Publication number
WO2016112374A3
WO2016112374A3 PCT/US2016/012797 US2016012797W WO2016112374A3 WO 2016112374 A3 WO2016112374 A3 WO 2016112374A3 US 2016012797 W US2016012797 W US 2016012797W WO 2016112374 A3 WO2016112374 A3 WO 2016112374A3
Authority
WO
WIPO (PCT)
Prior art keywords
rad3
atr
ataxia
inhibitors
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/012797
Other languages
French (fr)
Other versions
WO2016112374A2 (en
WO2016112374A9 (en
Inventor
Lee Zou
Rachel Litman FLYNN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of WO2016112374A2 publication Critical patent/WO2016112374A2/en
Publication of WO2016112374A3 publication Critical patent/WO2016112374A3/en
Publication of WO2016112374A9 publication Critical patent/WO2016112374A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for identifying and treating cancers, e.g., Alternative Lengthening of Telomeres (ALT)-positive cancers or cancers associated with accumulation of ssDNA, using Ataxia-Telangiectasia mutated and Rad3-related (ATR) inhibitors.
PCT/US2016/012797 2015-01-09 2016-01-11 Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) Ceased WO2016112374A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101415P 2015-01-09 2015-01-09
US62/101,415 2015-01-09

Publications (3)

Publication Number Publication Date
WO2016112374A2 WO2016112374A2 (en) 2016-07-14
WO2016112374A3 true WO2016112374A3 (en) 2016-09-01
WO2016112374A9 WO2016112374A9 (en) 2017-02-23

Family

ID=56356584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/012797 Ceased WO2016112374A2 (en) 2015-01-09 2016-01-11 Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)

Country Status (1)

Country Link
WO (1) WO2016112374A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3399983A1 (en) 2016-01-08 2018-11-14 The Institute of Cancer Research: Royal Cancer Hospital Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
CN106755430B (en) * 2016-12-28 2021-06-29 南开大学 Application of alternative mechanism of telomere elongation (ALT) as a marker of colorectal cancer stem cells
JOP20190197A1 (en) * 2017-02-24 2019-08-22 Bayer Pharma AG An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease
IT202000005527A1 (en) * 2020-03-16 2021-09-16 Univ Degli Studi Di Trento Therapeutic treatment of chromatinopathies
WO2025150911A1 (en) * 2024-01-09 2025-07-17 서울대학교 산학협력단 Composition for preventing or treating alternative lengthening of telomeres-positive cancer or aging

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120329047A1 (en) * 2009-09-22 2012-12-27 Roger Robert Reddel Methods and assays for the detection of alternative lengthening of telomeres (alt) activity in cells
WO2014140644A1 (en) * 2013-03-15 2014-09-18 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Chemical entities
WO2014188201A2 (en) * 2013-05-22 2014-11-27 Cancer Research Technology Limited Treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120329047A1 (en) * 2009-09-22 2012-12-27 Roger Robert Reddel Methods and assays for the detection of alternative lengthening of telomeres (alt) activity in cells
WO2014140644A1 (en) * 2013-03-15 2014-09-18 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Chemical entities
WO2014188201A2 (en) * 2013-05-22 2014-11-27 Cancer Research Technology Limited Treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FLYNN ET AL.: "Alternative Lengthening of Telomeres Renders Cancer Cells Hypersensitive to ATR Inhibitors.", SCIENCE, vol. 347, no. Issue 6219, 16 January 2015 (2015-01-16), pages 273 - 277 *
NABETANI ET AL.: "Localization of hRad9, hHus1, hRad1, and hRad17 and Caffeine sensitive DNA Replication at the Alternative Lengthening of Telomeres-associated Promyelocytic Leukemia Body.", J BIOL. CHEM., vol. 279, no. 4, 9 April 2004 (2004-04-09), pages 25849 - 25867 *

Also Published As

Publication number Publication date
WO2016112374A2 (en) 2016-07-14
WO2016112374A9 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
ZA202202559B (en) Kras g12c inhibitors and methods of using the same
MX2020011748A (en) Gene therapies for lysosomal disorders.
MX2020002502A (en) Inhibitors of kras g12c and methods of using the same.
MX2021012589A (en) Piperidine derivatives as inhibitors of ubiquitin specific protease 7.
IL265469A (en) Sample tracking via sample tracking chains, systems and methods
EP3794348A4 (en) Cell-free dna for assessing and/or treating cancer
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2017003478A (en) Anti-fgfr2/3 antibodies and methods using same.
MX2018016057A (en) Compositions and methods for treating cardiovascular disease.
MX2018009773A (en) Heteroaryl inhibitors of pad4.
WO2016065349A3 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MX2020005213A (en) Mk2 inhibitors and uses thereof.
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2018006632A (en) Bicyclic inhibitors of pad4.
EA201791133A1 (en) ERK INHIBITORS
MX2018016038A (en) Compounds and methods for modulating rna function.
MX2018006700A (en) Aza-benzimidazole inhibitors of pad4.
MY181693A (en) Dual quencher probes
MX2020006297A (en) VARIANTS OF CD19.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
EP4616910A3 (en) Pcna inhibitors
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
WO2016112374A3 (en) Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)
NZ741294A (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
TWI800489B (en) Fgfr4 inhibitors, and preparation methods and applications thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16735537

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16735537

Country of ref document: EP

Kind code of ref document: A2